Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

STRATA Skin Sciences (SSKN) EBIT (2016 - 2025)

STRATA Skin Sciences' EBIT history spans 14 years, with the latest figure at $3.9 million for Q4 2025.

  • On a quarterly basis, EBIT rose 190.46% to $3.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.3 million, a 85.82% increase, with the full-year FY2025 number at -$1.3 million, up 85.82% from a year prior.
  • EBIT hit $3.9 million in Q4 2025 for STRATA Skin Sciences, up from -$1.2 million in the prior quarter.
  • Over the last five years, EBIT for SSKN hit a ceiling of $3.9 million in Q4 2025 and a floor of -$4.3 million in Q4 2024.
  • Historically, EBIT has averaged -$1.4 million across 5 years, with a median of -$1.6 million in 2022.
  • Biggest five-year swings in EBIT: tumbled 2667.91% in 2023 and later soared 190.46% in 2025.
  • Tracing SSKN's EBIT over 5 years: stood at -$622000.0 in 2021, then skyrocketed by 121.54% to $134000.0 in 2022, then tumbled by 2667.91% to -$3.4 million in 2023, then fell by 24.53% to -$4.3 million in 2024, then skyrocketed by 190.46% to $3.9 million in 2025.
  • Business Quant data shows EBIT for SSKN at $3.9 million in Q4 2025, -$1.2 million in Q3 2025, and -$2.3 million in Q2 2025.